<DOC>
	<DOCNO>NCT01155817</DOCNO>
	<brief_summary>PRIMARY OBJECTIVES : Determine safety tolerability nilotinib steroid dependent / refractory cGVHD . SECONDARY OBJECTIVES : Determine clinical efficacy nilotinib steroid dependent / refractory cGVHD .</brief_summary>
	<brief_title>Phase 1 Nilotinib Steroid Dependent/Refractory Chronic Graft Versus Host Disease</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<criteria>5.1.1 Steroid dependent/refractory cGVHD define : 1 . Dependent disease Persistent cGVHD manifestation require glucocorticoid dose &gt; = prednisone 0.25 mg/kg/day ( 0.5 mg/kg po qod ) least 12 week . 2 . Refractory disease Progressive cGVHD manifestation despite treatment glucocorticoid dose &gt; = prednisone 0.5 mg/kg/day ( 1 mg/kg po qod ) least 4 week . 5.1.2 Any previous treatment cGVHD ( except nilotinib ) . Participants may receive nilotinib reason besides cGVHD leukemia solid tumor . 5.1.3 Participants must receive baseline systemic glucocorticoid therapy cGVHD study entry . The dose steroid must stable 14 day prior start nilotinib . 5.1.4 At time trial enrollment , participant may receive one two immunosuppressive therapy addition glucocorticoid . Immunosuppressant dos must stable 14 day prior start nilotinib . Monoclonal T B cell antibody must discontinue least 28 day start nilotinib . 5.1.5 Chronic GVHD manifestation follow physical laboratory exam . A list potential manifestation present Appendix D. 1 . Skin change 2 . Oral mucosa change 3 . Hepatic dysfunction 5.1.6 &gt; = 18 year old 5.1.7 Life expectancy &gt; = 6 month . 5.1.8 Karnofsky performance status &gt; = 60 ( define unable work , able live home , able care personal need require occasional assistance others ) . 5.1.9 Laboratory parameter : 1 . Creatinine &lt; 1.5 x ULN 2 . ANC &gt; 1.5 x 10^9/L 3 . Platelets &gt; 100 x 10^9/L 4 . Total bilirubin &lt; 1.5 x ULN 5 . AST ( SGOT ) ALT ( SGPT ) &lt; 2.5 x ULN 6 . Serum amylase lipase &lt; = 1.5 x ULN 7 . Alkaline phosphatase &lt; = 2.5 x ULN 8 . Patients must follow laboratory value within normal limit local institution lab correct within normal limit supplement prior first dose study medication : Potassium Magnesium Phosphorus Calcium 5.1.10 Oxygen saturation exertion maintain &gt; = 88 % room air . 5.1.11 Ability understand willingness sign write informed consent form . 5.1.12 Females reproductive potential must negative pregnancy test &lt; = 7 day start nilotinib . Reproductive potential define least 1 menstrual period past 12 month . Male female subject reproductive potential agree use barrier contraception treatment 3 month last dose . 5.1.13 Careful rationalization concomitant medication intent discontinue change alternative medication concomitant medication identify potential prolong QTcB interval associate increase risk torsades de pointes . ( Appendix B ) 5.1.14 . Careful rationalization concomitant medication intent discontinue change alternative medication concomitant medication identify strong CYP3A4 inhibitor . ( Appendix C ) 5.1.15 Myeloablative nonmyeloablative allogeneic hematopoietic cell transplant . 5.2.1 Currently receive receive within 28 day start study drug nilotinib tyrosine kinase inhibitor . 5.2.2 Received antiT antiB cell monoclonal antibody &lt; = 28 day prior anticipated start study drug . 5.2.3 Currently receive &gt; two immunosuppressant glucocorticoid . 5.2.4 Currently receive calcineurin inhibitor sirolimus 5.2.5 Received investigational agent &lt; = 28 day start nilotinib . 5.2.6 Impaired cardiac function include one following : 1 . Clinically significant rest brachycardia ( &lt; 50 beat per minute ) . 2 . QTc &gt; 450 msec baseline ECG . If QTc &gt; 450 msec electrolyte within normal range , electrolyte correct patient rescreened QTc . 3 . Myocardial infarction within 12 month prior start study . 4 . Other clinically significant uncontrolled heart disease ( e.g . unstable angina , congestive heart failure uncontrolled hypertension ) . 5 . History presence clinically significant ventricular atrial tachyarrhythmias . ( include congenital long QT syndrome know family history congenital long QT syndrome ) 5.2.7 Allogeneic cell infusion within 100 day 5.2.8 Uncontrolled infection responsive antibiotic , antiviral medicine , antifungal medicine . 5.2.9 Progressive malignant disease include post transplant lymphoproliferative disease . 5.2.10 Any secondary malignancy except basal squamous cell carcinoma skin within past five year . 5.2.11 Nilotinib intolerance hypersensitivity . 5.2.12 Impaired gastrointestinal ( GI ) function GI disease may significantly alter absorption study drug ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , small bowel resection gastric bypass surgery ) . 5.2.13 Acute chronic pancreatic disease 5.2.14 Major surgery within 4 week prior Day 1 study recover prior surgery . 5.2.15 Subject pregnant , breastfeeding , childbearing potential without negative serum urine pregnancy test within 7 day enrollment . Male female patient childbearing potential unwilling use effective contraceptive precaution throughout trial . 5.2.16 Subject willing comply treatment response evaluation ( include associate procedure skin biopsy ) . 5.2.17 Subject concurrent illness opinion investigator may interfere treatment evaluation patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>